Madoka Shiino

Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for <i>Helicobacter pylori</i> eradication: a phase III, randomised, double-blind study

Kazunari Murakami, Yuuichi Sakurai, Madoka Shiino et al. · Gut · 2016 · 420 citations · Full text

Evaluation of the Efficacy and Safety of Vonoprazan in Patients with Nonerosive Gastroesophageal Reflux Disease: A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study

Yoshikazu Kinoshita, Yuuichi Sakurai, Madoka Shiino et al. · Current Therapeutic Research · 2016 · 71 citations · Full text

A randomized, double-blind study to evaluate the acid-inhibitory effect of vonoprazan (20 mg and 40 mg) in patients with proton-pump inhibitor-resistant erosive esophagitis

Katsuhiko Iwakiri, Yuuichi Sakurai, Madoka Shiino et al. · Therapeutic Advances in Gastroenterology · 2017 · 62 citations · Full text

Pharmacokinetics and Safety of Triple Therapy with Vonoprazan, Amoxicillin, and Clarithromycin or Metronidazole: A Phase 1, Open-Label, Randomized, Crossover Study

Yuuichi Sakurai, Madoka Shiino, Hiroyuki Okamoto et al. · Advances in Therapy · 2016 · 40 citations

Drug Safety, Antibiotics, Triple Therapy +7

Pharmacokinetic Drug–Drug Interactions Between Vonoprazan and Low-Dose Aspirin or Nonsteroidal Anti-inflammatory Drugs: A Phase 2, Open-Label, Study in Healthy Japanese Men

Yuuichi Sakurai, Madoka Shiino, Sayako Horii et al. · Clinical Drug Investigation · 2016 · 17 citations · Full text